Opinion|Videos|January 10, 2025
Exploring Bispecifics in Earlier Lines of Therapy for B-Cell Lymphomas
Panelists discuss how several studies evaluating bispecific therapies in earlier lines of therapy for diffuse large B-cell lymphoma and follicular lymphoma suggest that patients with high-risk or relapsed/refractory disease are most likely to benefit from these treatments.
Advertisement
Episodes in this series
Video content above is prompted by the following:
Several studies are evaluating the use of bispecific therapies in earlier lines of therapy for both diffuse large B-cell lymphoma and follicular lymphoma. What patient populations are most likely to benefit from bispecific therapies in earlier lines of therapy?
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
COVID-19 May Follow a Different Seasonal Pattern Than Influenza, RSV
2
3 Considerations for Oncology Pharmacy Care Delivery: Minhee Kang, PharmD
3
Adam Kittai, MD, on Sequencing, Cost, and the Road to CLL Cure
4
Longer Sleep Linked to Lower Glycemic Variability, Reduced Deviation Risk in Adolescents
5